Xeris Biopharma (NASDAQ:XERS) Price Target Raised to $7.00
Xeris Biopharma (NASDAQ:XERS – Free Report) had its target price raised by Oppenheimer from $6.00 to $7.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an outperform rating on the stock. Several other research analysts have also commented on XERS. Leerink Partners lifted their target price on Xeris Biopharma from $5.00 to […]
